Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.
The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs.
Andrews
Mark
M
Discovery Chemistry, Pfizer Global Research and Development, Sandwich, United Kingdom.
Brown
Alan
A
Chiva
Jean-Yves
JY
Fradet
David
D
Gordon
David
D
Lansdell
Mark
M
MacKenny
Malcolm
M
D002460:Cell Line; D015195:Drug Design; D006801:Humans; D010880:Piperidines / Q000138:chemical synthesis / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000138:chemical synthesis* / Q000378:metabolism; D013329:Structure-Activity Relationship
D010880:Piperidines; D017367:Selective Serotonin Reuptake Inhibitors; C057048:litoxetine